Ad Astra Diagnostics develops the QScout® RLD, an imaging-based system that provides rapid leukocyte differential counts from a single drop of blood in approximately two minutes, utilizing AI for direct cell examination. This technology addresses the need for immediate and accurate white blood cell analysis, facilitating faster diagnosis of infections, including sepsis, without the complexities of traditional laboratory methods.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional complete blood count (CBC) testing requires sending samples to a central lab, resulting in delays that can hinder timely diagnosis and treatment, especially in point-of-care settings. Current point-of-care solutions may lack the accuracy and comprehensive analysis of central lab methods. This is especially critical in the early detection of severe infections like sepsis, where rapid results are essential.
Solution
Ad Astra Diagnostics offers the QScout® RLD, a rapid, point-of-care diagnostic system that delivers leukocyte differential counts from a single drop of blood in approximately two minutes. The system utilizes an imaging-based approach combined with artificial intelligence to directly examine cells, providing a complete blood count, including immature granulocytes, at the patient's side. This eliminates the need for lengthy machine startup or sample preparation, as well as wet reagents, enabling faster diagnosis and treatment decisions. The QScout® RLD aims to provide lab-quality results at a lab-grade cost, improving patient outcomes and healthcare efficiency.
Target Audience
The primary target audience includes healthcare providers in point-of-care settings, such as clinics, emergency departments, and urgent care centers, who require rapid and accurate CBC results for timely diagnosis and treatment decisions. Clinical investigators interested in clinical trials are also a target audience.
Features
- Imaging-based system for direct cell examination, avoiding the limitations of flow cytometry and Coulter Principle methods
- AI-powered analysis for rapid and accurate leukocyte differential counts
- Reports a white blood cell and differential count in approximately 2 minutes from a single drop of blood
- Measures immature granulocytes, an early marker of sepsis
- Requires no lengthy machine startup time or sample preparation
- Eliminates the need for wet reagents, simplifying operation and reducing waste
- Compact design for point-of-care use